Find any stock by ticker or company name
All rights reserved.
0.03
0.00 (0.00%)
All financial results are reported in Canadian dollars unless otherwise stated. Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Numinus Wellness Inc. (OTC Pink: NUMIF) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced that it has filed all quarterly interim financial reports for fiscal year 2026 to May 31, 2026.
Q4 Fiscal 2025 Highlights Revenue of $2.3 million, a 29.0% increase over Q3 2025 Gross profit of $1.4 million, compared to a gross profit of $0.8 million in Q3 2025 Cash position of $0.5 million as of August 31, 2025 Subsequent to Quarter End On April 18, 2026, President Donald Trump signed an executive order directing U.S. federal agencies to accelerate research, access, and regulatory review for psychedelic-based treatments, including psilocybin, ibogaine, MDMA, and LSD, and committing US$50 million in federal support for state-level programs. The Company views this as a meaningful regulatory development for its clinical research operations and practitioner training programs, both of which are actively engaged in psychedelic research delivery and practitioner readiness.
There is no data to display
